Please assess the completion status of the following clinical trial:

Trial Title: A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must sign an Informed Consent Form~* In remission from past HE~* Uses appropriate birth control measures~* More than or equal to 18 years of age~* Must have potential to benefit from treatment~* Recent prior HE episodes~* Capable and willing to comply with all study procedures~* Participant has personal support available~* Has a certain Model End Stage Liver Disease (MELD) score~* Recent transjugular intrahepatic portosystemic shunt (TIPS) placement or revision~Exclusion Criteria:~* Significant medical conditions, medical conditions that may impact study participation, or Investigator decision not to include~* Allergies to the study drug or similar drugs~* Laboratory abnormalities~* Recent participation in another clinical trial~* History of non-compliance~* Pregnant or at risk of pregnancy, or is lactating~* Recent alcohol consumption~* Active bacterial or viral Infections~* Bowel issues~* Active malignancy~* On a prohibited medication~* Liver transplant expected in near term~* Lactulose intolerance~* Participant shows presence of intestinal obstruction or has inflammatory bowel disease~* Ongoing or recent GI bleed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rifaximin (Type: EXPERIMENTAL): Participants were administered a single rifaximin 550 milligram (mg) tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.
- Placebo (Type: PLACEBO_COMPARATOR): Participants were administered a single matching placebo tablet 2 times per day (approximately every 12 hours) for 6 months or until a breakthrough episode of hepatic encephalopathy or another reason for discontinuation.

Based on this trial design, predict the completion outcome and termination type (if applicable).